Chembio Diagnostics - 14 Year Stock Price History | CEMI

Historical daily share price chart and data for Chembio Diagnostics since 2004 adjusted for splits and dividends. Open, high, low, close (OHLC) data as well as percentage changes for multiple date ranges. Display 20, 50 and 200 day moving averages and export charts as images to use in articles and blogs. The latest closing price for Chembio Diagnostics as of October 19, 2018 is 9.65.
Chembio Diagnostics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2018 9.3063 8.1000 11.5000 7.0500 9.6500 17.68%
2017 6.2502 6.6500 8.3500 5.2500 8.2000 20.59%
2016 6.7890 5.2100 9.1200 4.2800 6.8000 27.58%
2015 4.5294 3.8700 5.3400 3.5600 5.3300 36.32%
2014 3.5915 3.4000 4.7300 2.8700 3.9100 16.02%
2013 4.4190 4.7501 5.7100 3.2900 3.3700 -28.75%
2012 4.3034 3.4400 5.2599 3.2800 4.7300 40.77%
2011 3.4753 3.2800 4.5600 2.4800 3.3600 -1.18%
2010 2.1713 2.1600 3.6400 1.5200 3.4000 51.79%
2009 1.3250 0.8800 2.9600 0.6400 2.2400 154.55%
2008 1.3837 1.9200 2.4000 0.6000 0.8800 -59.26%
2007 4.6029 6.1600 7.2000 2.1600 2.1600 -67.47%
2006 5.8140 3.0400 8.2400 2.6400 6.6400 137.14%
2005 4.8378 5.7600 6.5600 2.4400 2.8000 -51.39%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.137B $0.024B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $126.867B 19.45
Abbott Laboratories (ABT) United States $118.574B 24.05
Stryker (SYK) United States $63.182B 24.41
Boston Scientific (BSX) United States $50.532B 26.29
Baxter (BAX) United States $37.110B 25.26
Zimmer Biomet Holdings (ZBH) United States $25.314B 16.26
ResMed (RMD) United States $14.694B 29.17
Smith & Nephew SNATS (SNN) United Kingdom $14.608B 0.00
Canopy Growth (CGC) Canada $10.780B 0.00
Perrigo (PRGO) Ireland $9.837B 13.96
Bio-Rad Laboratories (BIO) United States $8.382B 53.82
Hill-Rom Holdings (HRC) United States $5.797B 19.66
Haemonetics (HAE) United States $5.495B 50.15
ICU Medical (ICUI) United States $5.418B 36.71
Insulet (PODD) United States $5.203B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $4.301B 0.00
Hutchison China MediTech (HCM) China $4.012B 0.00
Agios Pharmaceuticals (AGIO) United States $3.879B 0.00
Neogen (NEOG) United States $3.281B 49.69
NuVasive (NUVA) United States $3.191B 30.27
National Vision Holdings (EYE) United States $3.137B 69.28
Quidel (QDEL) United States $2.525B 51.73
NxStage Medical (NXTM) United States $1.815B 0.00
Phibro Animal Health (PAHC) United States $1.784B 25.40
Cardiovascular Systems (CSII) United States $1.263B 727.80
AtriCure (ATRC) United States $1.071B 0.00
VAREX IMAGING (VREX) United States $0.985B 16.09
Owens & Minor (OMI) United States $0.934B 9.99
OraSure Technologies (OSUR) United States $0.904B 59.08
Cerus (CERS) United States $0.887B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.874B 25.81
PetIQ (PETQ) United States $0.862B 28.18
Surmodics (SRDX) United States $0.843B 101.77
MacroGenics (MGNX) United States $0.792B 0.00
Omeros (OMER) United States $0.770B 0.00
Insys Therapeutics (INSY) United States $0.662B 0.00
Meridian Bioscience (VIVO) United States $0.660B 22.57
LeMaitre Vascular (LMAT) United States $0.542B 26.97
Lantheus Holdings (LNTH) United States $0.517B 16.07
NanoString Technologies (NSTG) United States $0.452B 0.00
TG Therapeutics (TGTX) United States $0.445B 0.00
Quanterix (QTRX) United States $0.398B 0.00
Evolus (EOLS) United States $0.354B 0.00
Utah Medical Products (UTMD) United States $0.325B 20.90
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.323B 0.00
Cytosorbents (CTSO) United States $0.321B 0.00
Surface Oncology (SURF) United States $0.220B 0.00
Rockwell Medical (RMTI) United States $0.218B 0.00
BioLife Solutions (BLFS) United States $0.204B 0.00
Bovie Medical (BVX) United States $0.173B 0.00
Chimerix (CMRX) United States $0.173B 0.00
Fonar (FONR) United States $0.149B 7.32
Conatus Pharmaceuticals (CNAT) United States $0.144B 0.00
United-Guardian (UG) United States $0.080B 17.61
Female Health (VERU) United States $0.075B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.074B 0.00
Trinity Biotech (TRIB) Ireland $0.071B 21.31
Imprimis Pharmaceuticals (IMMY) United States $0.070B 0.00
InfuSystems Holdings (INFU) United States $0.062B 0.00
Neurotrope (NTRP) United States $0.057B 0.00
CAS Medical Systems (CASM) United States $0.055B 0.00
ImmuCell (ICCC) United States $0.045B 0.00
Akers Biosciences Inc (AKER) United States $0.034B 0.00
Valeritas Holdings (VLRX) United States $0.031B 0.00
Capricor Therapeutics (CAPR) United States $0.027B 0.00
Myomo (MYO) United States $0.023B 0.00
Senestech (SNES) United States $0.020B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.019B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.009B 0.00